111 related articles for article (PubMed ID: 29749668)
1. Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection.
Feldman SF; Lapidus N; Dorival C; Diallo A; Amri I; Fontaine H; Pol S; Carrat F;
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):797-805. PubMed ID: 29749668
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
Laurain A; Metivier S; Haour G; Larrey D; Dorival C; Hezode C; Zoulim F; Marcellin P; Bourliere M; Zarski JP; Thabut D; Alric L; Ganne-Carrie N; Cales P; Bronowicki JP; Riachi G; Geist C; Causse X; Abergel A; Chazouilleres O; Mathurin P; Guyader D; Samuel D; Tran A; Loustaud-Ratti V; Petrov-Sanchez V; Diallo A; Luzivika-Nzinga C; Fontaine H; Carrat F; Pol S;
BMC Infect Dis; 2019 Apr; 19(1):300. PubMed ID: 30940090
[TBL] [Abstract][Full Text] [Related]
3. Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.
Ahmed EI; Abdel Wahed WY; Hassan EA; Ahmed TI
Curr Drug Saf; 2018; 13(3):187-195. PubMed ID: 30009714
[TBL] [Abstract][Full Text] [Related]
4. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr
J Hepatol; 2016 Oct; 65(4):734-740. PubMed ID: 27288051
[TBL] [Abstract][Full Text] [Related]
5. Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV).
Abbas M; Patrizia C; Fabienne M; Marc B; Lucia P; Fabrice C; Martin D; Camelia P
Qual Life Res; 2024 Jun; 33(6):1527-1540. PubMed ID: 38580786
[TBL] [Abstract][Full Text] [Related]
6. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
Carrieri P; Bourlière M; Di Beo V; Lusivika-Nzinga C; Ramier C; Antwerpes S; Protopopescu C; Lacombe JM; Pol S; Fontaine H; Mourad A; Carrat F; Duracinsky M; Marcellin F;
Qual Life Res; 2023 Dec; 32(12):3427-3438. PubMed ID: 37587323
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus cure from direct-acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort).
Barré T; Bourlière M; Parlati L; Ramier C; Marcellin F; Protopopescu C; Di Beo V; Cagnot C; Dorival C; Nicol J; Zoulim F; Carrat F; Carrieri P;
Drug Alcohol Rev; 2024 Mar; 43(3):718-731. PubMed ID: 38133601
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
10. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
[TBL] [Abstract][Full Text] [Related]
12. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
Lawitz E; Poordad F; Gutierrez JA; Kakuda TN; Picchio G; Beets G; Vandevoorde A; Van Remoortere P; Jacquemyn B; Luo D; Ouwerkerk-Mahadevan S; Vijgen L; Van Eygen V; Beumont M
J Viral Hepat; 2017 Apr; 24(4):287-294. PubMed ID: 27878906
[TBL] [Abstract][Full Text] [Related]
13. Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort.
Lam L; Fontaine H; Lapidus N; Bellet J; Lusivika-Nzinga C; Nicol J; Dorival C; Cagnot C; Hejblum G; Pol S; Bourlière M; Carrat F;
J Viral Hepat; 2023 Mar; 30(3):232-241. PubMed ID: 36529681
[TBL] [Abstract][Full Text] [Related]
14. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
[TBL] [Abstract][Full Text] [Related]
15. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
16. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
17. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort).
Santos M; Protopopescu C; Delarocque-Astagneau E; Bourlière M; Petrov-Sanchez V; Di Beo V; Larrey D; Baudoin M; Dorival C; Bureau M; Fontaine H; Carrat F; Marcellin F; Pol S; Carrieri P;
Liver Int; 2022 Jan; 42(1):38-49. PubMed ID: 34520614
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
[TBL] [Abstract][Full Text] [Related]
19. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.
Manns MP; Fried MW; Zeuzem S; Jacobson IM; Forns X; Poordad F; Peeters M; Fu M; Lenz O; Ouwerkerk-Mahadevan S; Jessner W; Scott JA; Kalmeijer R; De La Rosa G; Sinha R; Beumont-Mauviel M
J Viral Hepat; 2015 Apr; 22(4):366-75. PubMed ID: 25363449
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy.
Bagheri H; Fouladi A; Barange K; Lapeyre-Mestre M; Payen JL; Montastruc JL; Vinel JP
Pharmacotherapy; 2004 Nov; 24(11):1546-53. PubMed ID: 15537560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
